
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is a radiopharmaceutical development company that has a promising technology utilizing alpha-emitting isotope Lead-212 for targeted cancer therapy. With a potential $39 billion addressable market and upcoming data catalysts for all three clinical programs in 2026, the company is well-positioned to become a frontrunner in the TAT space. However, risks to the attainment of the price target and rating include potential competition and difficulties with reimbursement and adoption of products.
Bears say
Perspective Therapeutics is a radiopharmaceutical company that has a potentially promising TAT treatment for cancer, as evidenced by pre-clinical data and support from key opinion leaders. However, the frontloading regimen and potential side effects may pose risks to adoption and reimbursement, which could negatively impact overall market potential and valuation for Perspective Therapeutics. It will be important to closely monitor clinical data and competition in the market for this company's success and potential stock performance.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares